Home

Greenwich LifeSciences, Inc. - Common stock (GLSI)

12.00
+0.22 (1.87%)

Greenwich Lifesciences Inc is a biotechnology firm focused on advancing innovative therapies for cancer treatment, particularly in the realm of immunotherapy

The company is dedicated to developing its novel drug candidates to harness the body's immune system in targeting and destroying cancer cells. Through rigorous research and clinical trials, Greenwich Lifesciences aims to provide effective treatment options for patients, with a specific emphasis on improving outcomes and quality of life for those affected by various types of cancer. The firm's commitment to scientific excellence and patient-centric approaches positions it at the forefront of cancer therapeutics.

SummaryNewsPress ReleasesChartHistoricalFAQ